Molecular Networking for Drug Toxicities Studies: The Case of Hydroxychloroquine in COVID-19 Patients

Using drugs to treat COVID-19 symptoms may induce adverse effects and modify patient outcomes. These adverse events may be further aggravated in obese patients, who often present different illnesses such as metabolic-associated fatty liver disease. In Rennes University Hospital, several drug such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferron, Pierre-Jean, Le Daré, Brendan, Bronsard, Julie, Steichen, Clara, Babina, Elodie, Pelletier, Romain, Hauet, Thierry, Morel, Isabelle, Tarte, Karin, Reizine, Florian, Clément, Bruno, Fromenty, Bernard, Gicquel, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744768/
https://www.ncbi.nlm.nih.gov/pubmed/35008505
http://dx.doi.org/10.3390/ijms23010082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8744768/
https://www.ncbi.nlm.nih.gov/pubmed/35008505
http://dx.doi.org/10.3390/ijms23010082

Ejemplares similares